Duloxetine hydrochloride - 40 mg + placebo + Duloxetine hydrochloride - 60 mg
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetic Neuropathies
Conditions
Diabetic Neuropathies
Trial Timeline
Nov 1, 2007 → Mar 1, 2009
NCT ID
NCT00552175About Duloxetine hydrochloride - 40 mg + placebo + Duloxetine hydrochloride - 60 mg
Duloxetine hydrochloride - 40 mg + placebo + Duloxetine hydrochloride - 60 mg is a phase 3 stage product being developed by Shionogi for Diabetic Neuropathies. The current trial status is completed. This product is registered under clinical trial identifier NCT00552175. Target conditions include Diabetic Neuropathies.
What happened to similar drugs?
20 of 20 similar drugs in Diabetic Neuropathies were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00552175 | Phase 3 | Completed |
Competing Products
20 competing products in Diabetic Neuropathies